A rare epidermal growth factor receptor H773L/V774M compound mutation in advanced non‐small‐cell lung cancer with poor response to epidermal growth factor receptor tyrosine kinase inhibitor

類似資料

• The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
  著者:: Chang, Shih-Chieh, 等
  出版事項: (2011)
• IGFBP7 Drives Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition in Lung Cancer
  著者:: Wu, Shang-Gin, 等
  出版事項: (2019)
• Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor–tyrosine kinase inhibitors
  著者:: Huang-Chih Chang, 等
  出版事項: (2017-03-01)
• Epidermal growth factor receptor tyrosine kinase inhibitors
  著者:: Ranson, M
  出版事項: (2004)
• Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?
  著者:: Banno, Eri, 等
  出版事項: (2016)